EP.FRI.450 Gastrograffin use in Non-Adhesional Small bowel Obstruction

Aims Use of Gastrograffin (GG) radio-opaque contrast has been documented in the management of adhesional small bowel obstruction. It is not widely used in other causes of small bowel obstruction. The aim of this study was to assess the effectiveness of GG use in non-adhesive small bowel obstructions. Methods A retrospective review of patients who had GG administered following CT confirmed small bowel obstruction (SBO) over 2-year period was conducted. Demographics, cause of SBO and outcomes were recorded. The primary outcome was resolution of SBO with GG. Results 80 patients received GG for management of radiologically confirmed small bowel obstruction. The mean age was 62.7 years +/- 14.64 (SD) and M:F ratio was 1:1. The causes of small bowel obstruction included adhesions (n = 37, 46%), hernias (n = 17, 21%), progression of known cancer (n = 3, 4%). 18% (n = 15) had no clear cause of SBO on CT. In the adhesion group, GG resolved SBO in n = 27 (73%) of patients. In the hernia group 7 (41%) were incisional hernias and 7 (41%) were parastomal hernias. GG was given to both groups and the obstruction resolved in n = 6 (86%) and n = 4 (57%) of cases respectively. Conclusions This study shows the effective use of GG in hernia related SBO where there is no absolute indication for surgery. GG might be suitable for incisional and parastomal hernias as a bridge to resolving acute SBO allowing a delayed repair with complex techniques.

The case of a conservative caesarian reduction in case of absolute indication

Anamnesis. The pregnant OT is descended from a dwarf humpbacked father and a medium-sized woman mother; had a dwarf brother who died of diphtheria, a sister who died of an unknown cause and a healthy and living brother, both of which were no different from ordinary people.

Aktuelle Aspekte der Cholesteatomchirurgie – Teil 2: chirurgische Therapie im Wandel der Zeit

Due to cholesteatoma's slowly progressive and destructive growth there is a risk of intracranial and potentially life-threatening complications. That's why every cholesteatoma is a basically absolute indication for surgery. Only asymptomatic and small retractions, so-called prae-cholesteatomas, may be under observation. While the first part of this article focused on the basics of pathogenesis and diagnostics, this one provides an overview of current surgical strategies, both proven and new ones.

Reduction in the procedure time of hybrid endoscopic submucosal dissection for early gastric neoplasms: a multi-center retrospective propensity score-matched analysis

Background: Endoscopic submucosal dissection (ESD) for early gastric neoplasms is still a technically difficult and time-consuming procedure. Hybrid ESD (H-ESD) involves circumferential incision with partial submucosal dissection combined with subsequent mucosal resection by snaring, wherein the newly developed device allows us to perform H-ESD using a single device. This study aimed to determine the clinical outcomes of H-ESD compared with conventional ESD (C-ESD) for early gastric neoplasms. Methods: In this multi-center, retrospective study, using propensity score-matched analysis, we reviewed the charts of patients with early gastric neoplasms smaller than 20 mm treated with H-ESD or C-ESD at three hospitals between January 2017 and October 2018. The primary outcome was the procedure time, and the secondary outcomes were other factors, including the en bloc resection rate, complete resection rate, curative resection rate, and rate of adverse events. Results: Among 215 patients, 29 underwent H-ESD and 186 underwent C-ESD; 29 pairs were created by propensity score matching. In the H-ESD group, 82.8% of lesions met the absolute indication [mucosal lesions limited to 20-mm diameter, dominated by differentiated adenocarcinoma without ulcer (scar)] for endoscopic resection (ER). As a result, the procedure time of H-ESD was significantly shorter than that of C-ESD [20 (interquartile range, 12–27) min versus 40 (30–50) min; p < 0.001]. There was no significant difference in the secondary outcomes between the two groups. Conclusion: H-ESD contributed to reduced procedure time. Therefore, H-ESD could be an alternative endoscopic treatment for gastric neoplasms when the lesion fulfils the absolute indication for ER.